TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd.

TTPEX:6549
5.94
TWD
0.00
(0.00%)
574.47MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
0.89
- -
0.29
0.2
0.3
- -
- -
- -
Basic EPS, GAAP
-3.89
-3.45
-3.03
-4.74
-3.38
-3.5
-0.07
-0.6
-0.16
-1.22
-0.08
-0.29
-0.3
- -
Free Cash Flow per Basic Share
-8.18
-6.58
-5.02
-4.3
-3.17
-1.73
0.22
-0.6
-0.13
-0.3
-0.03
-0.3
-0.31
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3
12.89
10.03
6.04
4.77
2.2
2.15
2.33
2.17
0.95
0.89
1.19
0.89
0.8
Tangible Book Value per Share
2.4
8.25
5.39
1.13
0.98
0.84
1.07
1.3
1.15
0.94
0.88
1.19
0.89
0.8
Basic Weighted Avg Shares
4
28
47
47
55
68
69
71
75
76
75
77
80
80
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
62
- -
22
15
23
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-10.84
- -
-44.09
-557.77
-29.07
- -
- -
- -
Depreciation Expense
3
- -
1
2
2
1
22
1
1
76
2
2
2
- -
Net Income, GAAP
-17
-98
-142
-223
-186
-238
-5
-42
-12
-92
-6
-22
-24
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
566.76
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-8.24
- -
-56.32
-602.19
-26.59
- -
- -
- -
Working Capital
90
410
263
50
59
55
69
93
82
64
58
87
68
61
LT Debt
- -
- -
- -
- -
- -
- -
1
- -
- -
1
- -
- -
1
1
Total Equity
149
642
499
284
290
154
152
176
163
72
67
95
71
64
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
20.3
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
-3.37
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-24.76
-24.96
-56.93
-64.82
-107.12
-3.32
-25.92
-7.32
-78.67
-8.73
-27.58
-29.33
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
80
80
80
Market Capitalization
625
618
574

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
79
73
66
Cash, Cash Equivalents & STI
73
68
60
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
5
4
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-12.66%
-10.63%
-25.39%
Free Cash Flow
31.29%
172.76%
8.12%
Net Income, GAAP
146.41%
151.73%
8.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.29
2025
- -
- -
-0.3
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Hung Chang Yuan
Full Time Employees
13
Sector
Health technology
Industry
Biotechnology
Address
No.2 ShengYi Road Hsinchu Taiwan 302058
IPO Date
Oct 21, 2015
Business
TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO) develops and commercializes small-molecule therapeutics targeting chronic organ inflammation from metabolic, autoimmune, and infectious causes, with a focus on liver diseases, allergy, and asthma; its pipeline includes re-profiled approved drugs via the 505(b)(2) pathway such as JKB-122, a long-acting TLR4 antagonist for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and liver fibrosis demonstrating anti-fibrotic, immuno-modulating, and anti-inflammatory effects, and JKB-121; novel chemical entities (NCEs) such as TJC-0265, an autotaxin inhibitor for NASH and idiopathic pulmonary fibrosis (IPF), TJC-0434, TJC-0545, and TJC-0667 addressing core technologies including TLR4, autotaxin, NOX, and HDAC for indications like kidney injury, inflammatory bowel disease, rheumatoid arthritis, asthma, and atopic dermatitis. The company operates primarily in Taiwan, seeking product development collaborations and strategic alliances to advance its pipeline. Founded in 2011 and headquartered in Zhubei City, Hsinchu County, Taiwan, TaiwanJ employs around 13 people and lists on the Taipei Exchange. Recent developments include reporting earnings for the half-year ended June 30, 2024, and ongoing Phase II clinical activities for key candidates like JKB-122, with no major acquisitions, funding rounds, or new partnerships announced in 2024 or 2025.